Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283644 | 0.77 | ALDH1A1 (0.44) | ALDH1A1TSHR | |
| Ammonia Solution, Strong SCHEMBL5978210 | 0.75 | ALDH1A1 (0.42) | ALDH1A1TSHR | |
| SCHEMBL28704882 | 0.75 | ALDH1A1 (0.42) | ALDH1A1TSHR | |
| SCHEMBL15632930 | 0.73 | ALDH1A1 (0.36) | CTSSCTSKCTSLCTSBDPP4 | |
| SCHEMBL16796407 | 0.73 | ALDH1A1 (0.36) | CTSSCTSKCTSLCTSBDPP4 | |
| SCHEMBL20262433 | 0.69 | ALDH1A1 (0.36) | ALDH1A1TSHR | |
| Formamide SCHEMBL28190515 | 0.67 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| SCHEMBL27282597 | 0.67 | CTSS (0.38) | CTSSCTSKCTSLCTSBDPP4 | |
| SCHEMBL20565192 | 0.67 | DPP4 (0.35) | CTSSCTSKCTSLCTSBDPP4 | |
| SCHEMBL18730442 | 0.67 | CTSS (0.33) | CTSSCTSKCTSLCTSBDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193343-A1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193343-A1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE3A, PRKG1, PDE2A | CTSS 4328/4885CTSK 3932/4885CTSL 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.